AxoGen (NASDAQ:AXGN) Director Sells $70,162.20 in Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell sold 1,647 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $42.60, for a total transaction of $70,162.20. Following the transaction, the director directly owned 93,826 shares of the company’s stock, valued at approximately $3,996,987.60. This represents a 1.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

AxoGen Stock Up 1.6%

Shares of AXGN opened at $40.95 on Friday. The company has a 50-day simple moving average of $35.19 and a 200-day simple moving average of $31.97. The firm has a market capitalization of $2.18 billion, a P/E ratio of -63.98 and a beta of 1.17. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.33 and a current ratio of 7.10. AxoGen, Inc. has a 52 week low of $9.22 and a 52 week high of $45.83.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). The company had revenue of $61.46 million for the quarter, compared to analyst estimates of $57.85 million. AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. On average, equities research analysts expect that AxoGen, Inc. will post -0.3 earnings per share for the current year.

Institutional Trading of AxoGen

Several large investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its stake in AxoGen by 1.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 21,473 shares of the medical equipment provider’s stock worth $703,000 after buying an additional 371 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of AxoGen by 6.2% during the first quarter. PNC Financial Services Group Inc. now owns 8,943 shares of the medical equipment provider’s stock valued at $296,000 after purchasing an additional 525 shares during the last quarter. Arax Advisory Partners grew its stake in shares of AxoGen by 362.4% during the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 819 shares during the last quarter. Brooklyn Investment Group grew its stake in shares of AxoGen by 4.2% during the fourth quarter. Brooklyn Investment Group now owns 20,568 shares of the medical equipment provider’s stock valued at $688,000 after purchasing an additional 823 shares during the last quarter. Finally, MCF Advisors LLC bought a new stake in shares of AxoGen during the fourth quarter valued at approximately $30,000. 80.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AXGN shares. Canaccord Genuity Group upped their price objective on shares of AxoGen from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Citigroup reaffirmed an “outperform” rating on shares of AxoGen in a research report on Wednesday, April 29th. HC Wainwright upped their price objective on shares of AxoGen from $39.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen lowered shares of AxoGen from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Citizens Jmp upped their price objective on shares of AxoGen from $42.00 to $50.00 and gave the company a “market outperform” rating in a research report on Wednesday, April 29th. Nine research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.